



Additional file 4


A)



B)



C)



Supplementary Fig. 3 Time to sustained EDSS progression by ≥ 2 versus 0–1 active T2 lesions at 6 months.

(a) Placebo/delayed treatment group; (b) IFN β -1a 22 μ g SC tiw group; (c) IFN β -1a 44 μ g SC tiw group.

A Cox proportional hazards model, adjusted for number of relapses in the previous 2 years, age, baseline EDSS score, and baseline burden of disease, was used to estimate hazard ratios and *p* values. *p* values are for time to first progression over 4 years.

CI: confidence interval; EDSS: Expanded Disability Status Scale; IFN β -1a: interferon beta-1a; SC: subcutaneously; tiw: three times weekly.